Introduction to
Sinogen Pharmaceutical

Guangzhou Sinogen Pharmaceutical Co., Ltd. is a biotechnology company committed to the development and production of innovative biological oncology drugs to meet the global demand for the treatment of a broad malignant tumors.

Since its establishment in 2016, under the leadership of Dr. Allan Zhao and other three nationally distinguished experts, and through the joint efforts of dozens of researchers, the company has gradually established the world's first rapid broad-spectrum oncolytic bacteria technology platform, and completed the preclinical study, the development of CMC manufacturing process, and the construction of GMP-compliant large-scale production facilities of the core product, an oncolytic bacteria, named as SalMet-Vec    . Our first-in-class product SalMet-Vec    has obtained the IND approvals from US FDA , Taiwan FDA and China NMPA, and has launched international multi-center phase I/IIa clinical trials for a variety of malignant solid tumors in the United States, Taiwan region and mainland China.

®

®

Science and Products

The oncolytic bacteria product SalMet-Vec     developed by Sinogen has a unique mechanism of action and therapeutic potentials for a broad-spectrum of malignancies. It can be administered by multiple routes and in combination with other oncology drugs. The investigator-initiated clinical studies have preliminarily confirmed its safety and remarkable efficacy.

®

News and information

Guangzhou Sinogen Pharmaceutical Co.，Ltd.all rights reserved 粤ICP备20063851号

Address：Room 101, 1st Floor, Building C5, Science and Technology Enterprise Accelerator, Huangpu District, Guangzhou Email : sinogen@sinogen.cc Service Time : Work days 9:00 ~ 17:00